You are here: Industry Insights > Ocugen

News List

Ocugen to buy Liminal’s vaccine manufacturing facility in Canada pharmaceutical-business-review
January 28, 2022
US-based Ocugen has signed a letter of intent (LOI) to acquire Liminal Biosciences’ manufacturing site located in Belleville...
Ocugen, Inc. Announces Submission of Emergency Use Authorization Request to the US FDA for Investigational COVID-19 Vaccine COVAXIN™ (BBV152) for Children Ages 2-18 Years AmericanPharmaceuticalReview
November 08, 2021
Ocugen, Inc., a biopharmaceutical company focused on discovering, developing, and commercializing novel therapeutics and vaccines, announced today that it has submitted a request to the U.S. Food...
Ocugen seeks FDA EUA for Covid-19 vaccine use in children Pharmaceutical-Technology
November 08, 2021
Ocugen has sought Emergency Use Authorization (EUA) from the US Food and Drug Administration (FDA) for its Covid-19 vaccine candidate, BBV152, for use in children in the age group of two to 18 years.
Ocugen seeks approval for Covaxin in Canada expresspharma
July 19, 2021
The move follows the release by Bharat Biotech of Phase 3 clinical trial results, which demonstrated efficacy and safety in nearly 25,800 adults, it said.
Ocugen commences rolling submission of COVAXIN to Health Canada pharmaceutical-technology
July 16, 2021
Ocugen has commenced the rolling submission to Health Canada for its Covid-19 vaccine candidate, COVAXIN, which is being jointly developed with Bharat Biotech International for use in the US and Canada.
Jubilant HollisterStier partners with Ocugen to make Covaxin for US, Canadian markets expresspharma
June 17, 2021
Jubilant HollisterStier has manufacturing units in Spokane (US) and Montreal (Canada).
Ocugen and Jubilant Enter COVID-19 Vaccine Partnership contractpharma
June 16, 2021
Jubilant HollisterStier to manufacture COVAXIN for the U.S. and Canadian markets.
Ocugen to seek full approval for Bharat Biotech’s Covaxin in the US pharmaceutical-technology
June 15, 2021
Ocugen has plans to seek full approval for Bharat Biotech’s Covid-19 vaccine candidate, Covaxin, in the US, after the Food and Drug Administration (FDA) declined to grant an Emergency Use Authorization (EUA).
Ocugen to apply for full US FDA approval of Covaxin, not for EUA expresspharma
June 15, 2021
Ocugen said the decision was based on a recommendation from the US FDA, which also requested more information and data for full approval.
Bharat Biotech gets $15 mn upfront from Ocugen for rights to commercialise Covaxin in Canada expresspharma
June 09, 2021
Ocugen has agreed to pay another $10 million to Bharat Biotech within a month from the commercial launch of Covaxin in Canada.

Previous page 1 2 Next page